Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overcoming T cell exhaustion in infection and cancer
Kristen E. Pauken, E. John Wherry
Trends in Immunology (2015) Vol. 36, Iss. 4, pp. 265-276
Open Access | Times Cited: 990

Showing 26-50 of 990 citing articles:

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal Patel, Andy J. Minn
Immunity (2018) Vol. 48, Iss. 3, pp. 417-433
Open Access | Times Cited: 493
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Angeliki M. Stamatouli, Zoe Quandt, Ana Luisa Perdigoto, et al.
Diabetes (2018) Vol. 67, Iss. 8, pp. 1471-1480
Open Access | Times Cited: 489
Immune checkpoints and their inhibition in cancer and infectious diseases
Lydia Dyck, Kingston H. G. Mills
European Journal of Immunology (2017) Vol. 47, Iss. 5, pp. 765-779
Open Access | Times Cited: 480
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Adil Daud, Kimberly Loo, Mariela Pauli, et al.
Journal of Clinical Investigation (2016) Vol. 126, Iss. 9, pp. 3447-3452
Open Access | Times Cited: 473
Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer
Anusha-Preethi Ganesan, James Clarke, Oliver Wood, et al.
Nature Immunology (2017) Vol. 18, Iss. 8, pp. 940-950
Open Access | Times Cited: 471
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang, Ming Chen, Hong Nie, et al.
Human Vaccines & Immunotherapeutics (2019) Vol. 15, Iss. 5, pp. 1111-1122
Open Access | Times Cited: 462
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan, Dong Zhang, Chunxiao Xu, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 424
Open Access | Times Cited: 431
Engineering CAR-T cells: Design concepts
Shivani Srivastava, Stanley R. Riddell
Trends in Immunology (2015) Vol. 36, Iss. 8, pp. 494-502
Open Access | Times Cited: 426
Epigenetic control of CD8+ T cell differentiation
Amanda N. Henning, Rahul Roychoudhuri, Nicholas P. Restifo
Nature reviews. Immunology (2018) Vol. 18, Iss. 5, pp. 340-356
Open Access | Times Cited: 424
The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer
Roy M. Bremnes, Lill‐Tove Busund, Thomas L. Kilvær, et al.
Journal of Thoracic Oncology (2016) Vol. 11, Iss. 6, pp. 789-800
Open Access | Times Cited: 420
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
Lakshmi Nayak, Fábio M. Iwamoto, Ann S. LaCasce, et al.
Blood (2017) Vol. 129, Iss. 23, pp. 3071-3073
Open Access | Times Cited: 417
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Soyoung Oh, Dai-Chen Wu, Jeanne Cheung, et al.
Nature Cancer (2020) Vol. 1, Iss. 7, pp. 681-691
Closed Access | Times Cited: 358
Programming CAR-T cells to kill cancer
Louai Labanieh, Robbie G. Majzner, Crystal L. Mackall
Nature Biomedical Engineering (2018) Vol. 2, Iss. 6, pp. 377-391
Open Access | Times Cited: 353
Pharmacological targeting of endoplasmic reticulum stress in disease
Stefan J. Marciniak, Joseph E. Chambers, David Ron
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 2, pp. 115-140
Closed Access | Times Cited: 336
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Xiaolei Li, Changshun Shao, Yufang Shi, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 321
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy
Anand Rotte, Jiangtao Jin, Vincent Lemaire
Annals of Oncology (2017) Vol. 29, Iss. 1, pp. 71-83
Open Access | Times Cited: 319
Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells
Jie Feng, Hui Yang, Yiqun Zhang, et al.
Oncogene (2017) Vol. 36, Iss. 42, pp. 5829-5839
Closed Access | Times Cited: 308
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
John R. Webb, Katy Milne, David R. Kroeger, et al.
Gynecologic Oncology (2016) Vol. 141, Iss. 2, pp. 293-302
Open Access | Times Cited: 305
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
Sylvain Simon, Nathalie Labarrière
OncoImmunology (2017) Vol. 7, Iss. 1, pp. e1364828-e1364828
Open Access | Times Cited: 304
An NK-like CAR T cell transition in CAR T cell dysfunction
Charly R. Good, M. Ángela Aznar, Shunichiro Kuramitsu, et al.
Cell (2021) Vol. 184, Iss. 25, pp. 6081-6100.e26
Open Access | Times Cited: 266
T cell metabolic fitness in antitumor immunity
Peter J. Siska, Jeffrey C. Rathmell
Trends in Immunology (2015) Vol. 36, Iss. 4, pp. 257-264
Open Access | Times Cited: 265
Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment
Yangjing Zhao, Qixiang Shao, Guangyong Peng
Cellular and Molecular Immunology (2019) Vol. 17, Iss. 1, pp. 27-35
Open Access | Times Cited: 265
Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy
Weiqin Jiang, Yinjun He, Wenguang He, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 257
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
Andy J. Minn, E. John Wherry
Cell (2016) Vol. 165, Iss. 2, pp. 272-275
Open Access | Times Cited: 251
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Paul E. Hughes, Sean Caenepeel, Lawren C. Wu
Trends in Immunology (2016) Vol. 37, Iss. 7, pp. 462-476
Closed Access | Times Cited: 251

Scroll to top